诺华COPD药物QVA149 首批3项III期研究达主要目标

2012-04-16 potato 生物谷

2012年4月2日，瑞士制药巨头诺华（Novartis）公司周一宣布，有关QVA149治疗慢性阻塞性肺病（chronic obstructive pulmonary disease，COPD）的首批3项III期研究均达到了预期的主要目标。 QVA149，一种具双重作用模式的支气管扩张剂，是诺华公司在其Breezhaler单剂量干粉吸入器中的第三个创新药物。诺华公司称，SHINE、BRIGHT

2012年4月2日，瑞士制药巨头诺华（Novartis）公司周一宣布，有关QVA149治疗慢性阻塞性肺病（chronic obstructive pulmonary disease，COPD）的首批3项III期研究均达到了预期的主要目标。

QVA149，一种具双重作用模式的支气管扩张剂，是诺华公司在其Breezhaler单剂量干粉吸入器中的第三个创新药物。

诺华公司称，SHINE、BRIGHT、ENLIGHTEN 3项III期研究证明了QVA149在治疗慢性阻塞性肺病中的潜能。这3项III期研究是IGNITE III期临床试验项目的关键组成部分，该项将为提交QVA149的新药申请（NDA）奠定基础。

SHINE研究表明，通过第一秒用力呼气容积谷值评价（in trough FEV1，Forced Expiratory Volume in 1 Second），QVA149比茚达特罗（indacaterol）及NVA237更具优势，此项研究达到了预期的主要目标。（indacaterol和NVA237均为诺华公司COPD药物）

BRIGHT研究表明，与安慰剂相比，患者的运动耐力得到了显着提高；ENLIGHTEN研究表明，QVA149具有与安慰剂相似的良好耐受性及安全性。

诺华制药开发负责人Tim Wright称，"IGNITE III期临床项目达到了预期的主要目标，这标志着在证明QVA149治疗COPD的潜力方面取得了重大进展，该药预计将成为我们强大的慢性阻塞性肺部药物产品中的第三个创新药。"

诺华表示，有关IGNITE研究项目的数据将在提交至今年晚些时候召开的医学大会。（生物谷bioon.com）

编译自：RTT News
http://www.rttnews.com/1852202/novartis-lung-disease-drug-qva149-meet-primary-endpoints-in-phase-iii-studies.aspx?type=qf

相关阅读

FDA委员会支持批准诺华肺病治疗药Indacaterol上市

慢性阻塞性肺病市场每年高达90亿美元

诺华与葛兰素史克在呼吸系统药物市场展开竞争

2012年新药研发展望

谁将成为下一个重磅炸弹？历数15个最有力的竞争者

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (5)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1915754, encodeId=b1361915e54fe, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 17:51:00 CST 2013, time=2013-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021308, encodeId=cd1a202130896, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Wed Nov 14 21:51:00 CST 2012, time=2012-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282601, encodeId=9e5f12826015f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545498, encodeId=e6241545498de, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594311, encodeId=64c61594311ff, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2013-02-22 juliusluan78

#III#

45 0
[GetPortalCommentsPageByObjectIdResponse(id=1915754, encodeId=b1361915e54fe, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 17:51:00 CST 2013, time=2013-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021308, encodeId=cd1a202130896, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Wed Nov 14 21:51:00 CST 2012, time=2012-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282601, encodeId=9e5f12826015f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545498, encodeId=e6241545498de, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594311, encodeId=64c61594311ff, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-11-14 HinsMax

#III期研究#

62 0
[GetPortalCommentsPageByObjectIdResponse(id=1915754, encodeId=b1361915e54fe, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 17:51:00 CST 2013, time=2013-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021308, encodeId=cd1a202130896, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Wed Nov 14 21:51:00 CST 2012, time=2012-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282601, encodeId=9e5f12826015f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545498, encodeId=e6241545498de, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594311, encodeId=64c61594311ff, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-04-18 一叶知秋

#诺华#

53 0
[GetPortalCommentsPageByObjectIdResponse(id=1915754, encodeId=b1361915e54fe, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 17:51:00 CST 2013, time=2013-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021308, encodeId=cd1a202130896, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Wed Nov 14 21:51:00 CST 2012, time=2012-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282601, encodeId=9e5f12826015f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545498, encodeId=e6241545498de, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594311, encodeId=64c61594311ff, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-04-18 jingyanzhu715_39486105

#COPD药物#

56 0
[GetPortalCommentsPageByObjectIdResponse(id=1915754, encodeId=b1361915e54fe, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Fri Feb 22 17:51:00 CST 2013, time=2013-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2021308, encodeId=cd1a202130896, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9574, encryptionId=69d595e421, topicName=III期研究)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/qXbLjJB4FSzhQS3C5qQFMJkqicRIJFL6zHFwwhv0I95nzA6xicevQcEica0gk4A58UkbMMriadAgTY2b7N7Yd0ZsQg/132, createdBy=910c2500152, createdName=HinsMax, createdTime=Wed Nov 14 21:51:00 CST 2012, time=2012-11-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282601, encodeId=9e5f12826015f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545498, encodeId=e6241545498de, content=<a href='/topic/show?id=3bc05091eb' target=_blank style='color:#2F92EE;'>#COPD药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5091, encryptionId=3bc05091eb, topicName=COPD药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28d413759111, createdName=jingyanzhu715_39486105, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594311, encodeId=64c61594311ff, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 18 11:51:00 CST 2012, time=2012-04-18, status=1, ipAttribution=)]
2012-04-18 智智灵药

#III期#

42 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药械

诺华COPD药物QVA149 首批3项III期研究达主要目标

相关资讯

科室

工具

服务